What have we learned from cancer immunotherapy in the last 3 years?
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
What have we learned from cancer immunotherapy in the last 3 years?
Authors
Keywords
Immunotherapy, Melanoma, Efficacy, Survival, Sequencing
Journal
Journal of Translational Medicine
Volume 12, Issue 1, Pages 141
Publisher
Springer Nature
Online
2014-05-22
DOI
10.1186/1479-5876-12-141
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
- (2014) Paolo Antonio Ascierto et al. CANCER INVESTIGATION
- The perspective of immunotherapy
- (2014) Christian U. Blank CURRENT OPINION IN ONCOLOGY
- Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
- (2014) Vanna Chiarion Sileni et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
- (2014) Paola Queirolo et al. JOURNAL OF NEURO-ONCOLOGY
- Cancer treatment: The killer within
- (2014) Heidi Ledford NATURE
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
- (2013) J. D. Wolchok et al. ANNALS OF ONCOLOGY
- Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma
- (2013) M. Maio et al. ANNALS OF ONCOLOGY
- Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival
- (2013) J. Delyon et al. ANNALS OF ONCOLOGY
- Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
- (2013) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer
- (2013) Helen Angell et al. CURRENT OPINION IN IMMUNOLOGY
- Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma
- (2013) Michele Del Vecchio et al. EUROPEAN JOURNAL OF CANCER
- Design and development of therapies using chimeric antigen receptor-expressing T cells
- (2013) Gianpietro Dotti et al. IMMUNOLOGICAL REVIEWS
- Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression
- (2013) Y.-C. Lu et al. JOURNAL OF IMMUNOLOGY
- Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma
- (2013) Sofie Wilgenhof et al. JOURNAL OF IMMUNOTHERAPY
- Do BRAF inhibitors select for populations with different disease progression kinetics?
- (2013) Paolo Antonio Ascierto et al. Journal of Translational Medicine
- Which drug, and when, for patients with BRAF-mutant melanoma?
- (2013) Sekwon Jang et al. LANCET ONCOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab for Patients With Advanced Mucosal Melanoma
- (2013) M. A. Postow et al. ONCOLOGIST
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab
- (2012) Vafa Shahabi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma
- (2012) Richard Wu et al. CANCER JOURNAL
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
- (2012) P. A. Prieto et al. CLINICAL CANCER RESEARCH
- BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
- (2012) C. Liu et al. CLINICAL CANCER RESEARCH
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunotherapy earns its spot in the ranks of cancer therapy
- (2012) Drew Pardoll et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
- (2012) Paolo A Ascierto et al. Journal of Translational Medicine
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
- (2012) Anna Maria Di Giacomo et al. LANCET ONCOLOGY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Ipilimumab activity in advanced uveal melanoma
- (2012) Muhammad Adnan Khattak et al. MELANOMA RESEARCH
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Tipping Point for Combination Therapy: Cancer Vaccines With Radiation, Chemotherapy, or Targeted Small Molecule Inhibitors
- (2012) James W. Hodge et al. SEMINARS IN ONCOLOGY
- Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
- (2011) Riccardo Danielli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
- (2011) L. H. Butterfield et al. CLINICAL CANCER RESEARCH
- New Challenges in Endpoints for Drug Development in Advanced Melanoma
- (2011) A. Ribas et al. CLINICAL CANCER RESEARCH
- Cancer immunotherapy – revisited
- (2011) W. Joost Lesterhuis et al. NATURE REVIEWS DRUG DISCOVERY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth
- (2010) Josette Carnahan et al. MOLECULAR CANCER THERAPEUTICS
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?
- (2009) A. Ribas et al. CLINICAL CANCER RESEARCH
- A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
- (2009) C. Brignone et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
- (2008) J. D. Wolchok et al. ONCOLOGIST
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation